Company leverages Generative AI across case management processes, achieving 17% efficiency gains in case intake within three weeks

Boston, Massachusetts – December 11, 2025 – ArisGlobal, an AI-first technology company at the forefront of life sciences and creator of LifeSphere® , today announced that a leading global pharmaceutical company has gone live with LifeSphere® NavaX™, marking a rapid enterprise deployment of GenAI-enabled pharmacovigilance automation. 

The go-live includes two of NavaX’s advanced AI solutions: Dynamic Data Extraction and Narrative Generation. Together, these solutions automate the extraction of key case data and the creation of high-quality safety narratives, enabling the organization’s global safety teams to increase efficiency, improve accuracy, and accelerate case processing at scale. 

The implementation reflects the organization’s commitment to operational innovation and strong collaboration between ArisGlobal and the customer’s global safety, IT, and business process excellence teams. Within the first three weeks, the customer is seeing 17% efficiency gains in their case intake.

“We’re closing the year with exceptional momentum behind NavaX. Nearly one million cases are already being processed through NavaX, and we’re poised for exponential scale in 2026,” said Steve Nuckols, Chief Customer Officer at ArisGlobal. “The conversation around Generative AI in pharmacovigilance is no longer theoretical—it’s proven. Together with our customers, we’re delivering measurable, operational impact on workflows that have historically demanded significant time and investment.” 

This latest go-live underscores how rapidly the market is shifting toward AI-driven safety operations. As more global organizations evaluate their long-term operating models, NavaX is emerging as a strategic lever—helping leaders reimagine case processing, strengthen compliance readiness, and build the digital foundation required for next-generation pharmacovigilance.